Amneal Pharmaceuticals, Inc. - News - Press Releases

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Dec 23, 2004

IMPAX Laboratories Announces Retirement of CFO

Dec 22, 2004

IMPAX Launches Generic Version of Wellbutrin SR 200mg Tablets

Dec 06, 2004

IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Wellbutrin SR 200mg Tablets; Eleventh Approval in 2004

Nov 29, 2004

IMPAX to Present at First Albany Capital Growth Conference

Nov 16, 2004

IMPAX to Present at the Credit Suisse First Boston Healthcare Conference

Nov 09, 2004

IMPAX Reports Third Quarter 2004 Financial Results

Nov 05, 2004

IMPAX to Present at the 15th Annual CIBC Healthcare Conference

Nov 03, 2004

IMPAX Laboratories Postpones Third Quarter 2004 Financial Results Conference Call to Tuesday, November 9, 2004

Oct 27, 2004

Impax Laboratories to Hold Third Quarter 2004 Financial Results Conference Call Thursday, November 4, 2004

Oct 20, 2004

IMPAX to Present at C.E. Unterberg, Towbin Specialty Pharmaceutical Conference

Oct 01, 2004

IMPAX Announces Effectiveness of Registration Statement Relating to Resale of 1.250% Convertible Senior Subordinated Debentures Due 2024

Sep 24, 2004

IMPAX Receives Final FDA Approval for Oxycodone Hydrochloride Controlled Release Tablets, 80mg; Tenth Approval in 2004

Sep 15, 2004

IMPAX To Present at the Think Equity Partners' 2nd Annual Growth Conference

Sep 15, 2004

IMPAX to Present at the Banc of America Securities 34th Annual Investment Conference

Sep 08, 2004

IMPAX To Present at the 17th Annual Bear Stearns Health Conference

Sep 08, 2004

IMPAX and Teva Launch Omeprazole Delayed Release Capsules 20mg

Sep 01, 2004

IMPAX Comments on Lower Court Ruling Related to Generic Rilutek

Aug 04, 2004

IMPAX Announces Second Consecutive Profitable Quarter; Receives Three FDA Approvals in Second Quarter

Aug 02, 2004

IMPAX Receives Final FDA Approval for Metformin Hydrochloride Extended Release Tablets, 500mg; Ninth Approval in 2004

Jul 23, 2004

IMPAX Laboratories to Hold Second Quarter 2004 Financial Results Conference Call Wednesday, August 4, 2004

Jul 12, 2004

IMPAX Signs Distribution Agreements with Leiner Health Products, LLC for Loratadine Products

Jun 18, 2004

IMPAX Granted FDA 180-Day Exclusivity for Metformin HCl Extended Release Tablets, 500mg; Selectively Waived to TEVA Pharmaceuticals USA Inc.

Jun 15, 2004

IMPAX To Present at the Wachovia Securities 14th Annual Nantucket Equity Conference

Jun 14, 2004

IMPAX Files Registration Statement for Resale of Previously Issued 1.250% Convertible Senior Subordinated Debentures Due 2024

May 28, 2004

IMPAX Receives Final FDA Approval for Generic PROAMATINE; Eighth ANDA Approval in 2004

May 27, 2004

IMPAX Receives Final FDA Approval for Generic Version of Zyban; Seventh ANDA Approval in 2004

May 25, 2004

IMPAX to Present at the Friedman Billings Ramsey 8th Annual Growth Investor Conference

May 17, 2004

IMPAX Shareholders Re-Elect Board Members

May 17, 2004

IMPAX Receives Final FDA Approval for Generic Version of Sinemet CR; Sixth ANDA Approval in 2004

May 10, 2004

IMPAX Laboratories to Present at the Banc of America Health Care Conference

May 05, 2004

IMPAX Posts First Profitable Quarter Driven by Record Revenues; Received Five FDA Approvals in First Quarter

Apr 28, 2004

IMPAX Laboratories to Hold First Quarter 2004 Financial Results Conference Call Wednesday, May 5, 2004

Apr 19, 2004

IMPAX to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference

Mar 30, 2004

IMPAX Laboratories, Inc. Prices $82 Million of 1.250% Convertible Senior Subordinated Debentures

Mar 30, 2004

IMPAX Announces Proposed Private Placement of Convertible Senior Subordinated Debentures

Mar 23, 2004

IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004

Mar 22, 2004

IMPAX Receives Final FDA Approval for Generic Version of Wellbutrin SR 150 MG

Mar 08, 2004

IMPAX Receives Tentative FDA Approval for Generic Version of Tricor Tablets; Fourth ANDA Approval of 2004

Mar 05, 2004

IMPAX Receives Final FDA Approval for Generic Version of Claritin-D 24-Hour; Third ANDA Approval of 2004 for IMPAX

Feb 27, 2004

IMPAX Receives Tentative FDA Approval for Generic Version of Allegra-D

Feb 27, 2004

IMPAX to Present at Lehman Brothers Healthcare Conference

Feb 19, 2004

IMPAX To Present at Smith Barney Specialty Pharmaceuticals Conference

Feb 17, 2004

IMPAX Reports Fourth Quarter and 2003 Financial Results; Received 9 FDA Approvals; Filed 8 Applications in Year

Feb 10, 2004

IMPAX Laboratories Postpones Fourth Quarter 2003 Financial Results Conference Call to Tuesday, February 17, 2004

Feb 03, 2004

IMPAX Laboratories to Hold Fourth Quarter 2003 Financial Results Conference Call Wednesday, February 11, 2004

Jan 29, 2004

IMPAX Announces Favorable Decision in Wellbutrin SR Patent Appeal

Jan 29, 2004

IMPAX to Present at Merrill Lynch Global Pharma, Device and Biotech Conference

Jan 28, 2004

IMPAX Receives FDA Approval for Generic Versions of Wellbutrin SR; Final Approval Issued for the 100 mg Strength

Jan 21, 2004

IMPAX To Present at Piper Jaffray Healthcare Conference

Jan 08, 2004

IMPAX to Present at J.P. Morgan Healthcare Conference

Jan 06, 2004

IMPAX Announces Organizational Changes

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.86.0.1